Date: <u>07/27/2022</u> Your Name: <u>Xiang Wang</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None
Г	Devenent er henererie for	
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	M News
0	testimony	_ XNone
	testimony	
_		
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_ <b>X</b> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_ XNone
12	Receipt of equipment,	_ <b>X</b> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Diansheng Zhong</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None
Г	Devenent er henererie for	
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	M News
0	testimony	_ XNone
	testimony	
_		
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_ <b>X</b> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_ XNone
12	Receipt of equipment,	_ <b>X</b> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: Junping Zhang

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone
	educational events	
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Nan Du</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None
Г	Devenent er henererie for	
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	M News
0	testimony	_ XNone
	testimony	
_		
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_ <b>X</b> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_ XNone
12	Receipt of equipment,	_ <b>X</b> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: <u>Yuchuan Ren</u>

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: Jinghua Gao

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	<b>X</b> None	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Likun Liu</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	_ XNone	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Junyan Yu</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	_ XNone	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Xiaomei Li</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ XNone	

<b></b>		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Liwen Ma</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	_ XNone	

<b></b>		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: <u>Aiming Zang</u>

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

<b></b>		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: Mudan Yang

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

<b></b>		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: <u>Yan Zhang</u>

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Jun Guo</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ XNone	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Zheng Liu</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	_ XNone	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: <u>Zhanzhao Fu</u>

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

<b></b>		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: Junmei Jia

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

<b></b>		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: <u>Jianfeng Diao</u>

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

<b></b>		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Zaiwen Fan</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	_ XNone	

-		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u>

Your Name: Xiang Song

Manuscript Title: <u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Guozhong Li</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u></u>

Manuscript number (if known):\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	_ XNone	

-			
5	Payment or honoraria for	_ <b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events		
6	Payment for expert	_ <b>X</b> None	
	testimony		
7	Support for attending	<b>X</b> None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: 07/27/2022 Your Name: <u>Huaging Wang</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None
Г	Devenent er henererie for	
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	M News
0	testimony	_ XNone
	testimony	
_		
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_ <b>X</b> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_ XNone
12		_ <b>X</b> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Chunmei Bai</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ XNone
5	Payment or honoraria for	XNone
	lectures, presentations, speakers bureaus, manuscript writing or educational events	
6	Payment for expert	_ XNone
	testimony	
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ <b>X</b> None
12	Receipt of equipment,	V Name
12	materials, drugs, medical	XNone
	writing, gifts or other services	
13	Other financial or non-	_ <b>X</b> None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Mei Guan</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None
Г	Devenent er henererie for	
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	M News
0	testimony	_ XNone
	testimony	
_		
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_ <b>X</b> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_ XNone
12		_ <b>X</b> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: 07/27/2022 Your Name: <u>Xiubao Ren</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None			
3	Royalties or licenses	_ <b>X</b> None			

4	Consulting fees	_ XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert	_ XNone
	testimony	
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ <b>X</b> None
12	Dessint of any immont	M. Marca
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non-	_ <b>X</b> None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>07/27/2022</u> Your Name: <u>Ruixing Zhang</u> Manuscript Title:<u>Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer:</u> <u>a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)</u>

Manuscript number (if known):\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None			
3	Royalties or licenses	_ <b>X</b> None			

4	Consulting fees	_ XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert	_ XNone
	testimony	
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	_ <b>X</b> None
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ <b>X</b> None
12	Dessint of any immont	M. Marca
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non-	_ <b>X</b> None
	financial interests	

This research was funded by the National Natural Science Foundation of China (grant No. 61435001), and the CAMS Innovation Fund for Medical Sciences (grant No. 2016-I2M-1-001).

Please place an "X" next to the following statement to indicate your agreement: